secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akari Therapeutics Plc (AKTX)
CIK:        0001541157
Form:       8-K
Filed at:   2024-09-18T23:59:59+00:00
Accession:  0000950170-24-107824
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akari updates Peak Bio merger conditions, CEO compensation revised, pipeline prioritization
--------------------------------------------------------------------------------

- Merger with Peak Bio conditions include Peak Bio net cash > -$13.5M and PIPE net proceeds ≥ $10M; expected closing Q4 2024.
- Post-merger combined entity to focus on Peak Bio's ADC platform and Akari's PAS-nomacopan GA program; HSCT-TMA suspended.
- Interim CEO Samir Patel's monthly $50k compensation changed from shares to NQSOs with 2x ADS multiplier.
- PAS-nomacopan IND filing for geographic atrophy expected in 2025; preclinical data suggests 3-month+ intravitreal dosing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1541157/000095017024107824/0000950170-24-107824-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1541157/000095017024107824/aktx-20240913.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-107824

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer